Base de dados : MEDLINE
Pesquisa : D23.050.285.050 [Categoria DeCS]
Referências encontradas : 5102 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 511 ir para página                         

  1 / 5102 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29428032
[Au] Autor:Zhou L; Rui JA; Wang SB; Chen SG; Qu Q
[Ti] Título:Carbohydrate Antigen 19-9 Increases the Predictive Efficiency of α-Fetoprotein for Prognosis of Resected Hepatocellular Carcinoma.
[So] Source:Am Surg;84(1):80-85, 2018 Jan 01.
[Is] ISSN:1555-9823
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Serum α-fetoprotein (AFP) is a classical biomarker for both diagnosis and prognosis of hepatocellular carcinoma (HCC). However, its predictive efficiency for prognosis remains unsatisfactory. This study explores whether integrating AFP and carbohydrate antigen (CA) 19-9/carcinoembryonic antigen (CEA) increase its prognostic efficiency in HCC. A total of 67 HCC patients with complete record of AFP, CA19-9, and CEA, who underwent radical hepatectomy, were included. The sole and combined evaluations for prognostic significance of the three markers were performed. In the first, it was found by one-factor analysis that AFP was a univariate prognostic indicator for disease-free survival, but not overall survival, whereas CEA and CA19-9 were not statistically significant, although the latter was of marginally predictive significance for disease-free survival. Subsequently, it was revealed that combined evaluation of AFP and CA19-9, rather than AFP and CEA, distinguished overall and disease-free survival more effectively, compared with single ones. However, this combination was not significant in multivariate Cox regression analysis, thus needing further validation, especially in large-scale prospective investigations. The addition of vascular invasion to AFP/CA19-9 combination might provide enhanced predictive power for disease-free survival. Collectively, these results preliminarily suggest that CA19-9 increases the predictive efficiency of AFP for prognosis of HCC after resection.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/sangue
Biomarcadores Tumorais/sangue
Antígeno Carcinoembrionário/sangue
Carcinoma/diagnóstico
Neoplasias Hepáticas/diagnóstico
alfa-Fetoproteínas/metabolismo
[Mh] Termos MeSH secundário: Carcinoma/irrigação sanguínea
Carcinoma/cirurgia
Intervalo Livre de Doença
Hepatectomia
Seres Humanos
Neoplasias Hepáticas/sangue
Neoplasias Hepáticas/cirurgia
Valor Preditivo dos Testes
Prognóstico
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (Biomarkers, Tumor); 0 (Carcinoembryonic Antigen); 0 (alpha-Fetoproteins); 0 (carbohydrate antigen 199, human)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180212
[St] Status:MEDLINE


  2 / 5102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390568
[Au] Autor:Ma Y; Shao X
[Ad] Endereço:Gynecological Department.
[Ti] Título:Uterine fibroids with positive 18F-FDG PET/CT image and significantly increased CA19-9: A case report.
[So] Source:Medicine (Baltimore);96(51):e9421, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Uterine fibroids are the most common pelvic solid tumors and common to 25% of women. F-fluorodexyglucose (F-FDG) is an energy metabolism tracer. Although FDG is generally concentrated in malignant lesions with high glucose metabolism, it can also accumulate in normal tissues, benign lesions, and inflammatory sites. The exact mechanism of FDG uptake by uterine fibroids is not clear. Here, we report a case of uterine fibroids with positive F-FDG positron emission tomography/computed tomography (PET/CT) imaging and significantly increased CA19-9. PATIENTS CONCERNS: The patient was a 43-year-old woman and admitted to our hospital because of "1-year-extended menstrual periods." At admission, she had normal CA125, AFP, and CEA level and CA19-9>1000.00 U/mL. Gynecological transvaginal ultrasound found enlarged uterus with an anterior hypoechoic area of 3.9 × 4.2 cm. CT and contrast-enhanced CT showed significantly enhanced mass shadow on the left anterior wall of uterus. F-FDG PET/CT showed increased FDG metabolism of tumor in the anterior wall of the uterus. INTERVENTIONS: Laparoscopic hysterectomy was performed. DIAGNOSIS: Pathological examination demonstrated subserosal leiomyoma. OUTCOMES: Her CA19-9 level dropped to 91.50 U/mL 1 day after surgery. LESSONS: Significantly elevated CA19-9 was positioned in the uterus by PET/CT imaging, which not only avoided unnecessary gastrointestinal endoscopy and reduced the suffering of patients, but also strengthened the operation confidence in gynecologists.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/sangue
Leiomioma/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Feminino
Fluordesoxiglucose F18/metabolismo
Seres Humanos
Leiomioma/sangue
Leiomioma/metabolismo
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (carbohydrate antigen 199, human); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009421


  3 / 5102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173726
[Au] Autor:Sadraei SI; Reynolds MR; Trant JF
[Ad] Endereço:University of Windsor, Windsor, ON, Canada.
[Ti] Título:The Synthesis and Biological Characterization of Acetal-Free Mimics of the Tumor-Associated Carbohydrate Antigens.
[So] Source:Adv Carbohydr Chem Biochem;74:137-237, 2017.
[Is] ISSN:2162-5530
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Carcinomas express unique carbohydrates, known as tumor-associated carbohydrate antigens (TACAs), on their surface. These are potential targets for anticancer vaccines; however, to date, no such vaccine has reached the clinic. One factor that may complicate the success of this effort is the lability of the glycosidic bond. Acetal-free carbohydrates are analogues that lack the glycosidic linkage by replacing either the endo or exo oxygen with a methylene. This chapter summarizes the seminal syntheses of the mucin TACAs, provides an overview of common techniques for the synthesis of carbasugars and C-glycosides, reviews the syntheses published to date of acetal-free TACA analogues, and provides an overview of their observed biological activity. We conclude by offering a summation of the challenges remaining to the field biologically and the potential that acetal-free TACAs have of answering several basic questions in carbohydrate immunology.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/análise
Biomarcadores Tumorais/análise
Vacinas Anticâncer/uso terapêutico
Carboidratos/uso terapêutico
Neoplasias/diagnóstico
Neoplasias/tratamento farmacológico
[Mh] Termos MeSH secundário: Vacinas Anticâncer/síntese química
Vacinas Anticâncer/química
Carboidratos/síntese química
Carboidratos/química
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (Biomarkers, Tumor); 0 (Cancer Vaccines); 0 (Carbohydrates)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171206
[Lr] Data última revisão:
171206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  4 / 5102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28719662
[Au] Autor:Herbomel GG; Rojas RE; Tran DT; Ajinkya M; Beck L; Tabak LA
[Ad] Endereço:Section on Biological Chemistry, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America.
[Ti] Título:The GalNAc-T Activation Pathway (GALA) is not a general mechanism for regulating mucin-type O-glycosylation.
[So] Source:PLoS One;12(7):e0179241, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mucin-type O-glycosylation is initiated by the UDP-GalNAc polypeptide:N-acetylgalactosaminyltransferase (GalNAc-T) family of enzymes. Their activity results in the GalNAc α1-O-Thr/Ser structure, termed the Tn antigen, which is further decorated with additional sugars. In neoplastic cells, the Tn antigen is often overexpressed. Because O-glycosylation is controlled by the activity of GalNAc-Ts, their regulation is of great interest. Previous reports suggest that growth factors, EGF or PDGF, induce Golgi complex-to-endoplasmic reticulum (ER) relocation of both GalNAc-Ts and Tn antigen in HeLa cells, offering a mechanism for Tn antigen overexpression termed "GALA". However, we were unable to reproduce these findings. Upon treatment of HeLa cells with either EGF or PDGF we observed no change in the co-localization of endogenous GalNAc-T1, GalNAc-T2 or Tn antigen with the Golgi complex marker TGN46. There was also no enhancement of localization with the ER marker calnexin. We conclude that growth factors do not cause redistribution of GalNAc-Ts from the Golgi complex to the ER in HeLa cells.
[Mh] Termos MeSH primário: Mucinas/metabolismo
N-Acetilgalactosaminiltransferases/metabolismo
[Mh] Termos MeSH secundário: Antígenos Glicosídicos Associados a Tumores/metabolismo
Retículo Endoplasmático/efeitos dos fármacos
Retículo Endoplasmático/metabolismo
Ativação Enzimática/efeitos dos fármacos
Fator de Crescimento Epidérmico/farmacologia
Glicosilação/efeitos dos fármacos
Complexo de Golgi/efeitos dos fármacos
Complexo de Golgi/metabolismo
Células HeLa
Seres Humanos
Mucinas/química
Fator de Crescimento Derivado de Plaquetas/farmacologia
Transporte Proteico/efeitos dos fármacos
Transdução de Sinais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (Mucins); 0 (Platelet-Derived Growth Factor); 0 (Tn antigen); 62229-50-9 (Epidermal Growth Factor); EC 2.4.1.- (N-Acetylgalactosaminyltransferases); EC 2.4.1.41 (polypeptide N-acetylgalactosaminyltransferase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179241


  5 / 5102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28708980
[Au] Autor:Shi C; Xu X; Yu X; Du Z; Luan X; Liu D; Hu T
[Ad] Endereço:Department of Immunology, Binzhou Medical University, Yantai, PR China.
[Ti] Título:CD3/CD28 dynabeads induce expression of tn antigen in human t cells accompanied by hypermethylation of the cosmc promoter.
[So] Source:Mol Immunol;90:98-105, 2017 Oct.
[Is] ISSN:1872-9142
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Glycosylation is an important protein post-translational modification. In this process, the intermediate product, Tn antigen, arises from somatic mutations in core1ß3-galactosyltransferase-specific molecular chaperone (Cosmc), which is required for the formation of active core1ß3-galactosyltransferase (T-synthase). As a type of tumor-associated carbohydrate antigen, Tn antigen is mainly expressed in many human tumor cells and is absent in normal cells. Surprisingly, it is also expressed in normal activated T cells after in vitro stimulation, but the mechanism underlying its expression remains unclear. This study demonstrated that Tn antigen was expressed in activated T cells and that the percentage of positive (Tn ) cells increased and subsequently decreased within 72h after stimulation with CD3/CD28 Dynabeads, with peak expression occurring at 48h. During activation, interleukin-4 (IL-4) expression in the T-cell supernatant consistently increased with Tn cells, and was inversely correlated with serum interferon gamma (IFN-γ) levels. Compared with unactivated (without CD3/CD28 Dynabead stimulation) T cells, the level of T-synthase transcription in activated T cells did not significantly change, whereas T-synthase activity and Cosmc transcription significantly decreased, accompanied by a further increase in methylation of the Cosmc promoter. The results also showed that Cosmc transcription and translation decreased and then increased, and that Cosmc promoter methylation was a dynamic process during T cell activation. These data suggest that hypermethylation of the Cosmc promoter may induce the expression of Tn antigen in activated T cells.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/biossíntese
Chaperonas Moleculares/genética
Regiões Promotoras Genéticas/genética
Fator de Transcrição Sp1/metabolismo
Fator de Transcrição Sp3/metabolismo
Linfócitos T/metabolismo
[Mh] Termos MeSH secundário: Sítios de Ligação
Antígenos CD28/imunologia
Complexo CD3/imunologia
Células Cultivadas
Metilação de DNA
Galactosiltransferases/biossíntese
Glicosilação
Seres Humanos
Interferon gama/sangue
Interleucina-4/biossíntese
Ativação Linfocitária/imunologia
Microesferas
Linfócitos T/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (C1GALT1C1 protein, human); 0 (CD28 Antigens); 0 (CD3 Complex); 0 (IL4 protein, human); 0 (Molecular Chaperones); 0 (SP3 protein, human); 0 (Sp1 Transcription Factor); 0 (Sp1 protein, human); 0 (Tn antigen); 148710-94-5 (Sp3 Transcription Factor); 207137-56-2 (Interleukin-4); 82115-62-6 (Interferon-gamma); EC 2.4.1.- (C1GALT1 protein, human); EC 2.4.1.- (Galactosyltransferases)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE


  6 / 5102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28685541
[Au] Autor:Lei XF; Jia SZ; Ye J; Qiao YL; Zhao GM; Li XH; Chang H
[Ad] Endereço:Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
[Ti] Título:Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer.
[So] Source:J Biol Regul Homeost Agents;31(2):383-388, 2017 Apr-Jun.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Pancreatic cancer is characterized by rapid onset, high malignancy and high mortality, thus its early diagnosis is effective for improving the survival rate of patients. To discuss the values of detection of carbohydrate antigen (CA) 50, CA242 and CA199 in the diagnosis of pancreatic cancer, this study randomly selected 112 patients who were confirmed as having stage Ia~IIb pancreatic ductal adenocarcinoma (PDAC) in the Shandong Provincial Hospital, China, from May 2012 to May 2013 as a malignant group. One hundred patients with benign pancreatic lesions and 90 healthy people were selected in the same period as a benign group and a healthy control group, respectively. The levels of serum CA199, CA242 and CA50 were detected using electrochemiluminescence. Results demonstrated that the levels of serum CA199, CA242 and CA50 of the malignant group were significantly higher than those of the benign group and the healthy control group (P=0.001; P=0.003; P=0.000). The positive rate of the tumor markers of the malignant group was higher than that of the benign group and the healthy control group, and the differences had statistical significance (P=0.006; P=0.004; P=0.005). In the malignant group, sensitivity of CA199 was the highest (81.42%) as was the specificity of CA242 (80.14%). The detection of two or more markers could improve sensitivity (joint detection based on parallel tests) and specificity (joint detection based on serial tests). Thus the levels of serum tumor markers including CA199, CA242 and CA50 could be used as the assisted indicators for the diagnosis of early-stage PDAC. Joint detection of the three tumor markers is of great significance to improve the diagnostic sensitivity and accuracy of early PDAC.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/sangue
Biomarcadores Tumorais/sangue
Neoplasias Pancreáticas/sangue
Neoplasias Pancreáticas/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (Biomarkers, Tumor); 0 (carbohydrate antigen 199, human)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE


  7 / 5102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28675699
[Au] Autor:Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
[Ad] Endereço:Johannes Gutenberg University Mainz, University Medical Center - Institute of Immunology, Langenbeckstraße 1, Building 708, 55131, Mainz, Germany.
[Ti] Título:Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
[So] Source:ChemMedChem;12(17):1424-1428, 2017 Sep 07.
[Is] ISSN:1860-7187
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Breaking tolerance is crucial for effective tumor immunotherapy. We showed that vaccines containing tumor-associated human MUC1 glycopeptides induce strong humoral antitumor responses in mice. The question remained whether such vaccines work in humans, in systems where huMUC1 is a self-antigen. To clarify the question, mice transgenic in expressing huMUC1, mimicking the self-tolerant environment, and wild-type mice were vaccinated with a synthetic vaccine. This vaccine comprised STn and Tn antigens bound to a MUC1 tandem repeat peptide coupled to tetanus toxoid. The vaccine induced strong immune responses in wild-type and huMUC1-transgenic mice without auto-aggressive side effects. All antisera exhibited almost equivalent binding to human breast tumor cells. Similar increases of activated B-, CD4 T-, and dendritic cells was found in the lymph nodes. The results demonstrate that tumor-associated huMUC1 glycopeptides coupled to tetanus toxoid are promising antitumor vaccines.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/uso terapêutico
Neoplasias da Mama/prevenção & controle
Vacinas Anticâncer/uso terapêutico
Mucina-1/uso terapêutico
Fragmentos de Peptídeos/uso terapêutico
Toxoide Tetânico/uso terapêutico
Vacinas Sintéticas/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Antígenos Glicosídicos Associados a Tumores/química
Antígenos Glicosídicos Associados a Tumores/imunologia
Neoplasias da Mama/imunologia
Vacinas Anticâncer/química
Vacinas Anticâncer/imunologia
Feminino
Seres Humanos
Imunização
Células MCF-7
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
Mucina-1/química
Fragmentos de Peptídeos/química
Toxoide Tetânico/química
Toxoide Tetânico/imunologia
Vacinas Sintéticas/química
Vacinas Sintéticas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (Cancer Vaccines); 0 (MUC1 tandem repeat peptide); 0 (Mucin-1); 0 (Peptide Fragments); 0 (Tetanus Toxoid); 0 (Tn antigen); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1002/cmdc.201700387


  8 / 5102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28668856
[Au] Autor:Mariampillai AI; Cruz JPD; Suh J; Sivapiragasam A; Nevins K; Hindenburg AA
[Ad] Endereço:Department of Hematology and Oncology, NYU Winthrop Hospital, Mineola, NY, U.S.A.
[Ti] Título:Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
[So] Source:Anticancer Res;37(7):3649-3656, 2017 07.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cancer antigen CA72-4 is a tumor marker found to be elevated in a variety of human adenocarcinomas. Using the DRG TM-CA72-4, we quantified the elevation of CA72-4 compared to current United States Food And Drug Administration-approved tumor markers in various cancer types. MATERIALS AND METHODS: We conducted a prospective, single-center study enrolling 96 patients between March 2013 and August 2016 with different locally advanced, unresectable or metastatic cancer known to express CA72-4. Quantification of CA72-4 was performed according to the manufacturer's instructions using the DRG TM-CA72-4 enzyme-linked immunosorbent assay kit and the positivity rates were calculated. RESULTS: CA72-4 expression varied with tumoral site of origin, with the highest positivity rates found in pancreatic and ovarian malignancies. Correlation with clinical activity was also noted in some patients. CONCLUSION: CA72-4 may have a potential role as an adjunct to conventional biomarkers in disease monitoring of pancreatic, ovarian and colorectal carcinomas.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/metabolismo
Neoplasias da Mama/metabolismo
Neoplasias Gastrointestinais/metabolismo
Neoplasias Pulmonares/metabolismo
Neoplasias Ovarianas/metabolismo
[Mh] Termos MeSH secundário: Idoso
Biomarcadores Tumorais/metabolismo
Antígeno CA-19-9/metabolismo
Feminino
Seres Humanos
Testes Imunológicos/métodos
Masculino
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (Biomarkers, Tumor); 0 (CA-19-9 Antigen); 0 (CA-72-4 antigen)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170703
[St] Status:MEDLINE


  9 / 5102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28639911
[Au] Autor:Wang J; Liu J; Zhang G; Kong D
[Ad] Endereço:Department of Colorectal Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin, China.
[Ti] Título:Individualized proximal margin correlates with outcomes in gastric cancers with radical gastrectomy.
[So] Source:Tumour Biol;39(6):1010428317711032, 2017 Jun.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The length of proximal margin for gastrectomy remains controversial. The proximal margin and its relationships with clinicopathological variables and overall survival of 922 gastric cancers were retrospectively analyzed. Proximal margin was divided into four groups (0-2.0, 2.1-4.0, 4.1-6.0, and >6.0 cm). It indicated that the overall survival was improved with the increase of proximal margin. The proximal margin of 2.1-4.0 cm was associated with a better overall survival for gastric cancers with solitary-type (T1 and T2 stages, N0 stage, tumor-node-metastasis stages I and II, tumor size <5 cm, histological G1 and G2, and Bormann type I and II). Futhermore, proximal margin of 4.1-6.0 cm was associated with a better overall survival for gastric cancers with infiltrative-type (T3 and T4 stages, N1 stage, tumor-node-metastasis stage III, tumor size ⩾5 cm, histological G3 and G4, and Bormann type III and IV). Univariate analysis revealed that T stage, N stage, tumor-node-metastasis stage, histological grade, Bormann type, carcinoembryonic antigen, carbohydrate antigen 199, extent of gastrectomy, tumor location, and proximal margin were significantly associated with overall survival. Multivariate analysis revealed that tumor-node-metastasis stage, histological grade, Bormann type, carcinoembryonic antigen, carbohydrate antigen 199, extent of gastrectomy, and proximal margin were independent prognostic factors for gastric cancers with radical gastrectomy. In conclusion, the proximal margin was an independent prognostic factor for gastric cancer and should be decided individually. Proximal margin of 2.1-4.0 cm and 4.1-6.0 cm were needed for patients with solitary-type and infiltrative-type, respectively.
[Mh] Termos MeSH primário: Gastrectomia
Excisão de Linfonodo
Prognóstico
Neoplasias Gástricas/cirurgia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antígenos Glicosídicos Associados a Tumores/genética
Intervalo Livre de Doença
Feminino
Seres Humanos
Metástase Linfática
Masculino
Meia-Idade
Estadiamento de Neoplasias
Neoplasias Gástricas/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (carbohydrate antigen 199, human)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317711032


  10 / 5102 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28632300
[Au] Autor:Richard E; Pifferi C; Fiore M; Samain E; Le Gouëllec A; Fort S; Renaudet O; Priem B
[Ad] Endereço:Université Grenoble Alpes and CNRS, CERMAV, 601, rue de la chimie, 38000, Grenoble, France.
[Ti] Título:Chemobacterial Synthesis of a Sialyl-Tn Cyclopeptide Vaccine Candidate.
[So] Source:Chembiochem;18(17):1730-1734, 2017 Sep 05.
[Is] ISSN:1439-7633
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:A conjugatable form of the tumour-associated carbohydrate antigen sialyl-Tn (Neu5Ac-α-2,6-GalNAc) was efficiently produced in Escherichia coli. Metabolically engineered E. coli strains overexpressing the 6-sialyltransferase gene of Photobacterium sp. and CMP-Neu5Ac synthetase genes of Neisseria meningitidis were cultivated at high density in the presence of GalNAc-α-propargyl as the exogenous acceptor. The target disaccharides, which were produced on the scale of several hundreds of milligrams, were then conjugated by using copper(I)-catalysed azide-alkyne cycloaddition click chemistry to a fully synthetic and immunogenic scaffold with the aim to create a candidate anticancer vaccine. Four sialyl-Tn epitopes were introduced on the upper face of an azido-functionalised multivalent cyclopeptide scaffold, the lower face of which was previously modified by an immunogenic polypeptide, PADRE. The ability of the resulting glycoconjugate to interact with oncofoetal sialyl-Tn monoclonal antibodies was confirmed in ELISA assays.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/metabolismo
Escherichia coli/metabolismo
Vacinas Sintéticas/metabolismo
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Anticorpos Monoclonais/imunologia
Reações Antígeno-Anticorpo
Antígenos Glicosídicos Associados a Tumores/química
Antígenos Glicosídicos Associados a Tumores/genética
Antígenos Glicosídicos Associados a Tumores/imunologia
Vacinas Anticâncer/genética
Vacinas Anticâncer/imunologia
Vacinas Anticâncer/metabolismo
Cromatografia em Camada Delgada
Química Click
Ensaio de Imunoadsorção Enzimática
Epitopos/química
Epitopos/genética
Epitopos/imunologia
Epitopos/metabolismo
Engenharia Metabólica
Neisseria/enzimologia
Peptídeos Cíclicos/genética
Peptídeos Cíclicos/imunologia
Peptídeos Cíclicos/metabolismo
Photobacterium/enzimologia
Sialiltransferases/genética
Sialiltransferases/metabolismo
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antigens, Tumor-Associated, Carbohydrate); 0 (Cancer Vaccines); 0 (Epitopes); 0 (Peptides, Cyclic); 0 (Vaccines, Synthetic); 0 (sialosyl-Tn antigen); EC 2.4.99.- (Sialyltransferases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.1002/cbic.201700240



página 1 de 511 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde